[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100424268":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":50,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":20,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":20,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Cohort of patients with Fibromuscular Dysplasia","Intervention consists in blood\u002Furine sampling",[12,13],"Genetic: Genetic dissection of Fibromuscular Dysplasia","Other: Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia",[15,21],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"GENETIC","Genetic dissection of Fibromuscular Dysplasia","Blood sampling for genetic analysis aiming at unraveling the genetic basis of Fibromuscular Dysplasia",[9],null,{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"Search for diagnostic and prognostic biomarkers of Fibromuscular Dysplasia","Blood\u002Furine and in rare cases tissue sampling aiming at identifying biomarkers of Fibromuscular Dysplasia",[9],[26],{"name":27,"affiliation":5,"role":28},"Alexandre Persu, MD-PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":20,"email":33},"CONTACT","0032 2 764 63 06","alexandre.persu@uclouvain.be",[35],{"facility":36,"status":37,"city":38,"state":20,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Cliniques Universitaires Saint-Luc","RECRUITING","Brussels","1200","Belgium","BE",{"type":43,"coordinates":44},"Point",[45,46],4.34878,50.85045,{"lat":46,"lon":45},[49],{"name":27,"role":31,"phone":32,"phoneExt":20,"email":33},{"type":28,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PERSU Alexandre","Professor","100424268","europeaninternational-fmd-registry-and-initiative-100424268",false,"NCT04804683","European\u002FInternational FMD Registry and Initiative","The European\u002FInternational FMD Registry and Initiative (FEIRI), a Prospective Study","FEIRI","Inclusion Criteria:\n\n(i) Patients with established FMD, i.e at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD).\n\n(ii) Patients with Spontaneous Coronary Artery Dissection (SCAD) in whom at least one lesion of multifocal FMD (string-of beads) in extra-coronary arteries has been identified (\"SCAD-FMD\").\n\n(iii) Patients with so-called \"atypical FMD\" or \"FMD-like presentation\", i.e. patients presenting with at least one dissection or 2 aneurysms \\\u003C 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy.\n\nExclusion Criteria:\n\nDiagnosis based only on ultrasound (need for computed tomographic angiography , magnetic resonance angiography or catheter-based angiography to confirm the diagnosis)","ALL",{"count":63,"type":64},5000,"ESTIMATED","INTERVENTIONAL",[67],"NA","The main objectives of FEIRI are:\n\n(i) To describe the demographic and arterial characteristics of FMD and related diseases at a global scale and according to countries and\u002For ethnic origin\n\n(ii) To evaluate the incidence and predictors of novel FMD lesions and complications\n\n(iii) To explore the commonalities and differences between FMD, SCAD and so-called atypical FMD (patients with multiple dissections and\u002For aneurysms without string-of-beads, focal stenosis or evidence of inherited arteriopathy)\n\n(iv) To contribute to the unravelling of genetic, proteomic and molecular mechanisms underlying FMD and related diseases\n\nParticipation to the FEIRI study implies:\n\n(i) Collection of demographic and standard-of-care clinical data, both retrospectively (from the diagnosis of FMD to signature of the informed consent) and prospectively (on the occasion of standard-of-care follow-up).\n\n(ii) Optional participation to a biobank implying collection of blood, urine and, in rare cases of intervention, tissue samples for genomic and proteomic analysis and identification of diagnostic and prognostic biomarkers of FMD.\n\nParticipants will be enrolled in centres from over 20 countries in Europe and beyond.",[70],"Fibromuscular Dysplasia","2022-05-04",{"date":73,"type":74},"2022-05-05","ACTUAL",{"date":76,"type":74},"2021-03-11",{"date":78,"type":64},"2031-03-10",{"name":5,"class":6},1]